Shareholders of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will be pleased this week, given that the stock price is up 14% to US$10.08 following its latest first-quarter results. Revenues of US$146m beat analyst forecasts by14%, while the business broke even in terms of statutory earnings per share (EPS). The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGS:BCRX Earnings and Revenue Growth May 8th 2025

After the latest results, the eleven analysts covering BioCryst Pharmaceuticals are now predicting revenues of US$613.4m in 2025. If met, this would reflect a major 22% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with BioCryst Pharmaceuticals forecast to report a statutory profit of US$0.13 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$562.0m and losses of US$0.087 per share in 2025. So we can see there's been a pretty clear upgrade to expectations following the latest results, with a slight bump in revenues expected to lead to profitability earlier than previously forecast.

Check out our latest analysis for BioCryst Pharmaceuticals

It will come as no surprise to learn that the analysts have increased their price target for BioCryst Pharmaceuticals 9.3% to US$16.58on the back of these upgrades. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic BioCryst Pharmaceuticals analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$11.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the BioCryst Pharmaceuticals' past performance and to peers in the same industry. We would highlight that BioCryst Pharmaceuticals' revenue growth is expected to slow, with the forecast 30% annualised growth rate until the end of 2025 being well below the historical 42% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 17% annually. Even after the forecast slowdown in growth, it seems obvious that BioCryst Pharmaceuticals is also expected to grow faster than the wider industry.

Story Continues

The Bottom Line

The most important thing to take away is that there's been a clear step-change in belief around the business' prospects, with the analysts now expecting BioCryst Pharmaceuticals to become profitable next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that in mind, we wouldn't be too quick to come to a conclusion on BioCryst Pharmaceuticals. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for BioCryst Pharmaceuticals going out to 2027, and you can see them free on our platform here..

We don't want to rain on the parade too much, but we did also find 1 warning sign for BioCryst Pharmaceuticals that you need to be mindful of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments